People across a wide range of ages have
been prescribed SPINRAZA‡
‡Based on patients who have been prescribed Low Dose SPINRAZA.
Over a decade
The safety and efficacy of
SPINRAZA was evaluated in the
longest clinical
trial program in
SMA to date.
3x/year after initial loading doses
SPINRAZA is delivered directly to the cerebrospinal fluid (CSF), the area surrounding the spinal cord, allowing it to be distributed to the target tissues.
Extensive real-world experience with the Low Dose Regimen of SPINRAZA across a broad range of ages†
have been treated with
SPINRAZA worldwide
a broad age range of
patients has taken
SPINRAZA
have been treated with
SPINRAZA
§Based on commercial patients and early access patients receiving SPINRAZA worldwide as of April 2026.
||Based on patients receiving treatment with SPINRAZA in the US as of April 2026.
¶SPINRAZA clinical studies did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger patients. Pivotal studies did not include adult patients.